SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Audentes Therapeutics, Inc. – (NasdaqGS: BOLD)

BALA CYNWYD, December 10, 2019 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Audentes, Inc. (“Audentes” or “the Company”) (NasdaqGS:BOLD) for possible breaches of fiduciary duty and other violations of federal and state law in connection with proposed acquisition of the Company by Astellas Pharma, Inc. Under the terms of the agreement, Audentes shareholders will receive only $60.00 for each share of Audentes common stock owned.

The investigation concerns whether the Audentes Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Astellas is underpaying for the Company. The transaction may undervalue the Company. For example, the merger will provide Astellas with Audentes robust pipeline, including its lead program AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM).

If you own shares of Audentes stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.